“The current condition has exposed some structural weaknesses in the EU’s medicines offer chain and also a high dependence on non-EU nations for active pharmaceutical ingredients,” Kyriakides said. She proposed that offer chain concerns be tackled in an EU pharmaceutical tactic expected to be launch